Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KT 621

Next Previous
Drug Profile

KT 621

Alternative Names: KT-621

Latest Information Update: 08 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymera Therapeutics
  • Class Anti-infectives; Anti-inflammatories; Antiasthmatics; Skin disorder therapies; Small molecules
  • Mechanism of Action STAT6 transcription factor degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis
  • Phase I Immunological disorders

Most Recent Events

  • 30 Jun 2026 Kymera Therapeutics initiates enrollment in a phase-II BREADTH-EXT trial in Asthma in USA (PO) (NCT07677059)
  • 25 Jun 2026 Kymera Therapeutics completes enrolment in the phase II BROADEN2 trial for Atopic dermatitis (In adolescents, In adults, In the elderly) in South Korea, Australia, Canada, Czech Republic, Germany, Japan, Poland, South Korea, United States (PO) (NCT07217015)
  • 25 Jun 2026 Kymera Therapeutics plans a phase III trial for Atopic dermatitis by mid 2027

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top